Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Next-Generation Sequencing in Medicine (Upcoming)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Impaired parasympathetic function increases susceptibility to inflammatory bowel disease in a mouse model of depression
Jean-Eric Ghia, … , Patricia Blennerhassett, Stephen M. Collins
Jean-Eric Ghia, … , Patricia Blennerhassett, Stephen M. Collins
Published May 1, 2008
Citation Information: J Clin Invest. 2008;118(6):2209-2218. https://doi.org/10.1172/JCI32849.
View: Text | PDF
Research Article Neuroscience

Impaired parasympathetic function increases susceptibility to inflammatory bowel disease in a mouse model of depression

  • Text
  • PDF
Abstract

Clinical and experimental evidence indicates that intestinal inflammatory conditions can be exacerbated by behavioral conditions such as depression. The recent demonstration of a tonic counterinflammatory influence mediated by the vagus nerve in experimental colitis provides a potential link between behavior and gut inflammation. Here we show that experimental conditions that induced depressive-like behaviors in mice increased susceptibility to intestinal inflammation by interfering with the tonic vagal inhibition of proinflammatory macrophages and that tricyclic antidepressants restored vagal function and reduced intestinal inflammation. These results show that reserpine-induced monoamine depletion and maternal separation, 2 models for depression, produced a vulnerability to colitis by a mechanism involving parasympathetic transmission and the presence of gut macrophages. The tricyclic antidepressant desmethylimipramine protected against this vulnerability by a vagal-dependent mechanism. Together these results illustrate the critical role of the vagus in both the vulnerability to inflammation induced by depressive-like conditions and the protection afforded by tricyclic antidepressants and rationalize a clinical evaluation of both parasympathomimetics and tricyclic antidepressants in treatment of inflammatory bowel disease.

Authors

Jean-Eric Ghia, Patricia Blennerhassett, Stephen M. Collins

×

Figure 3

Effect of experimental depression on H&E staining.

Options: View larger image (or click on image) Download as PowerPoint
Effect of experimental depression on H&E staining.
(A) Appearance of...
(A) Appearance of a colon in a DSS-treated nonreserpinized mouse. (B) Appearance of a colon in a DSS-treated RM; DSS treatment was associated with areas of greater erosion and with more inflammatory cell infiltration. (C) DMI treatment significantly reduced infiltration. (D) Following VXP, DMI treatment did not appear to result in any significant improvement. Images were taken after 5 days DSS induction of colitis on RM (1 μg/d for 14 days) and nonreserpinized mice. DMI treatment (15 mg/kg) was initiated 2 days after the beginning of the reserpine (1 μg/d) treatment. H&E staining. Original magnification, ×100.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts